Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

Trial Profile

A Phase Ib Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Capecitabine (Primary) ; Varlitinib (Primary)
  • Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 02 Jan 2019 According to an ASLAN Pharmaceuticals media release, Varlitinib has demonstrated tumour shrinkage responses and durable disease stabilization in BTC patients in this phase 1b study.
    • 27 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top